Protagenic Therapeutics, Inc.
PTIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.00 | -0.10 |
| FCF Yield | -23.56% | -8.64% | -74.78% | -1.84% |
| EV / EBITDA | -6.08 | -2.79 | -0.39 | -27.74 |
| Quality | ||||
| ROIC | 25.30% | -6,011.62% | 1,639.33% | -162.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 200.00% |
| Cash Conversion Ratio | 0.33 | 0.23 | 0.74 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -28.05% | -9.29% | -30.28% | -341.55% |
| Safety | ||||
| Net Debt / EBITDA | -0.39 | 0.02 | 0.61 | 1.19 |
| Interest Coverage | -32.44 | -9.82 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 11.48 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -14,909.59 | -1,182.96 | -368.56 |